Treatment of neuroleptic-induced tardive dyskinesia with levetiracetam: A case series [5]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 215-216

  Bona, Joseph R ^a,b  

^a DeKalb County Board of Health   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZATROPINE; BUSPIRONE; CARBAMAZEPINE; CLOZAPINE; ESCITALOPRAM; ETIRACETAM; FLUPHENAZINE; GABAPENTIN; HALOPERIDOL; LITHIUM; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; VALPROIC ACID;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ADULT; AGED; BIPOLAR DISORDER; CASE STUDY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; HUMAN; LETTER; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; TARDIVE DYSKINESIA;

ADULT; AGED; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; TREATMENT OUTCOME;

EID: 33646700970     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000203823.60603.80     Document Type: Letter

References (14)

1. Blanchet PJ. Antipsychotic drug-induced movement disorders. Can J Neurol Sci. 2003;30(suppl 1):S101-S107.
2. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry. 1999;7:70-76.
3. Kane JM, Woerner M, Lieberman JA, et al. Tardive dyskinesia and drugs. Drug Dev Res. 1986;9:41-51.
4. Tollefson GD, Beasley CM, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry. 1997;154:1248-1254.
5. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry. 2004;65(suppl 9):16-20.
6. Baldessarini RJ, Tarsy D. Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia. Int Rev Neurobiol. 1979;21:1-45.
7. Cassady SL, Thaker GK, Moran M, et al. GABA agonist-induced changes in motor, oculomotor, and attention measures correlate in schizophrenics with tardive dyskinesia. Biol Psychiatry. 1992;32:302-311.
8. Ben-Menachem E. Levetiracetam: treatment in epilepsy. Expert Opin Pharmacother. 2003;4:2079-2088.
9. McGavin CL, John V, Musser WS. Levetiracetam as a treatment for tardive dyskinesia: a case report. [letter] Neurology. 2003;61:419-420.
10. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. [letter] Arch Gen Psychiatry. 1982;39:486-487.
11. Gehan E. A generalized Wilcoxon test for comparing arbitrarily singly censored samples. Biometrika. 1965;52:203-223.
12. Lieberman JA, Saltz BL, Johns CA, et al. The effects of clozapine on tardive dyskinesia. Br J Psychiatry. 1991;158:503-510.
13. Kane JM. Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol. 2001;11(suppl 4):S397-S403.
14. McGrath JJ, Soares-Weiser KVS. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev. 2000;2:CD000459.